Bacterial mRNA Vaccines: Programming Immunity Against Antimicrobial Resistance

Area of Science:

• Vaccinology
• Microbiology
• Biotechnology

Background:

• Antimicrobial resistance (AMR) is a growing global health crisis.
• Traditional vaccine development faces challenges with bacterial pathogens.
• Messenger RNA (mRNA) technology offers a rapid and flexible platform for vaccine development.

Purpose of the Study:

• To review recent advances in bacterial mRNA vaccine design.
• To summarize preclinical progress against key bacterial pathogens.
• To highlight emerging strategies for accelerating clinical translation of mRNA vaccines.

Main Methods:

• Review of current literature on mRNA vaccine technology for bacterial infections.
• Analysis of progress in antigen selection, mRNA engineering, and lipid nanoparticle (LNP) delivery systems.
• Exploration of emerging strategies including AI-guided antigen discovery and synthetic biology.

Main Results:

• Preclinical success has been demonstrated against Mycobacterium tuberculosis, Pseudomonas aeruginosa, and Streptococcus pneumoniae.
• Challenges remain in bacterial antigen expression, mucosal delivery, and immune response durability.
• Integration of AI and synthetic biology shows potential for overcoming existing barriers.

Conclusions:

• Bacterial mRNA vaccines are a promising strategy to combat antibiotic-resistant infections.
• Continued innovation in antigen design, mRNA engineering, and delivery systems is crucial.
• Emerging technologies are poised to accelerate the clinical translation of these vaccines.